In addition, the percentage of cells expressing the exhaustion marker LAG-3 at 10 days post-nucleofection was low in CAR-T cultures derived from CLL, HL, and MM patients (2.4–4%, n = 5), but it was slightly elevated in cells derived from DLBCL patients (9.9–22.8%, n = 3). The gene discussed is LAG3; the disease is diffuse large B-cell lymphoma.